NVO catalysts
Catalysts and events linked to NVO, newest first.
Do these developments change your position?
Review NVO alongside your other holdings and identify which decision deserves attention first.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
DateCardAvg 5d
- 2026-08-31Novo Nordisk Introduces Oral Wegovy and Vivani Implant Partnership → Bullish NVONVO-0.38%
- 2026-08-31Novo Nordisk advances oral Wegovy and Vivani implant partnership in GLP-1 raceNVO-0.38%
- 2026-08-31Novo Nordisk Introduces Oral Wegovy and Vivani Implant PartnershipNVO VANI-0.38%
- 2026-08-31Novo Nordisk Advances Oral Wegovy and Implant Program Against Eli Lilly LeadNVO-0.38%
- 2026-08-31Novo Nordisk advances Wegovy pill formulation and Vivani implant partnershipNVO VANI-0.38%
- 2026-08-31Novo Nordisk Advances Oral Wegovy and Implant Program Against Eli Lilly LeadLLY NVO VANI-0.38%
- 2026-08-31Novo Nordisk advances Wegovy pill formulation and Vivani implant partnershipLLY NVO VANI-0.38%
- 2026-08-31Novo Nordisk advances oral Wegovy and Vivani implant partnership in GLP-1 raceLLY NVO VANI-0.38%
- 2026-08-31Novo Nordisk Introduces Oral Wegovy and Vivani Implant PartnershipLLY NVO VANI-0.38%
- 2026-08-30Novo Nordisk Deploys Oral Wegovy and Vivani Delivery PartnershipNVO+2.17%
- 2026-08-30Novo Nordisk Introduces Wegovy Pill and Vivani Implant to Challenge LillyNVO+2.17%
- 2026-08-30Novo Nordisk Deploys Oral Wegovy and Vivani Delivery PartnershipNVO VANI+2.17%
- 2026-08-30Novo Nordisk Launches Oral Wegovy and Enters Vivani Drug Delivery Implant DealNVO VANI+2.17%
- 2026-08-30Novo Nordisk Introduces Wegovy Pill and Vivani Implant to Challenge LillyNVO VANI+2.17%
- 2026-08-30Novo Nordisk Introduces Oral Wegovy and Partners with Vivani on GLP-1 ImplantNVO VANI+2.17%
- 2026-08-30Novo Nordisk Deploys Oral Wegovy and Vivani Implant Delivery in GLP-1 RaceLLY NVO VANI+2.17%
- 2026-08-30Novo Nordisk Deploys Oral Wegovy and Vivani Delivery PartnershipLLY NVO VANI+2.17%
- 2026-08-30Novo Nordisk Launches Oral Wegovy and Partners with Vivani for GLP-1 ImplantsLLY NVO VANI+2.17%
- 2026-08-30Novo Nordisk Introduces Wegovy Pill and Partners on Long-Acting ImplantLLY NVO VANI+2.17%
- 2026-08-30Novo Nordisk Deploys Oral Wegovy and Vivani Delivery Implant Against LillyLLY NVO VANI+2.17%
- 2026-08-30Novo Nordisk Introduces Wegovy Pill and Vivani Implant to Challenge LillyLLY NVO VANI+2.17%
- 2026-08-30Novo Nordisk Introduces Oral Wegovy and Partners with Vivani on GLP-1 ImplantLLY NVO VANI+2.17%
- 2026-08-30Novo Nordisk Launches Oral Wegovy and Enters Vivani Drug Delivery Implant DealLLY NVO VANI+2.17%
- 2026-08-30Novo Nordisk Launches Oral Wegovy and Partners with Vivani on Implant DeliveryLLY NVO VANI+2.17%
- 2026-07-22Novo Nordisk Files Federal Lawsuit Against Eli Lilly Over GLP-1 AdsLLY NVO+7.03%
- 2026-07-22Study: GLP-1 drugs linked to lower alcohol-related hospitalizationsLLY NVO+7.03%
- 2026-07-22Study: GLP-1 drugs linked to lower alcohol-related hospitalizationsLLY NVO+7.03%
- 2026-07-22Novo Nordisk sues Eli Lilly over 'deceptive' GLP-1 advertisingLLY NVO+7.03%
- 2026-07-22Novo Nordisk Sues Eli Lilly Over GLP-1 AdsLLY NVO+7.03%
- 2026-07-22South Africa reviews 12 generic semaglutide applications, signaling potential entry of GLP-1 drugsAPN.SJ NVO ZAR+7.03%
- 2026-07-21Novo Nordisk Faces 2026 Transition Amid GLP-1 Pricing PressuresNVO+3.20%
- 2026-07-19Novo Nordisk to launch more affordable authorised copy of Ozempic in South Africa via Acino partnershipJ203.JO LHC.JO MEI.JO NVO-3.08%
- 2026-07-18Novo Nordisk to launch cheaper Ozempic copy in South Africa via Acino partnershipJ203 NVO USDZAR-3.08%
- 2026-07-11Novo Nordisk Down 75% from Peak Amid Value Trap DebateLLY NVO+1.70%
- 2026-06-17GLP-1 Market Projected to Reach $95.3B by 2035LLY NVO+9.47%
- 2026-06-17GLP-1 Market Projected to Reach $95.3B by 2035; LLY and NVO LeadLLY NVO+9.47%
- 2026-05-26Eli Lilly's Mounjaro Dominates International GLP-1 MarketLLY NVO-2.87%
- 2026-05-26Morgan Stanley highlights Eli Lilly's GLP-1 dominance over Novo NordiskLLY NVO-2.87%
- 2026-05-21Eli Lilly Obesity Drug Retatrutide Shows 28.3% Weight Loss in Phase 3 TrialLLY NVO XBI+2.81%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.